PPARG and lung cancer: This may further contribute to the apoptosis inducing synergistic action of TS in the combination treatment since other PPARγ agonists have been demonstrated to increase ROS levels in lung cancer cells by altering glucose metabolism to reduce glutathione levels ultimately resulting in cell cycle arrest36.